Yoh Isobe
Yoh Isobe publishes mostly in Surgery, Pulmonary and Respiratory Medicine and Gastroenterology, on topics such as Gastric Cancer Management and Outcomes, Helicobacter pylori-related gastroenterology studies and Gastrointestinal Tumor Research and Treatment.
- World rank
- #1,743,824 of 7,710,434 ranked researchers
- Rank in Japan
- #29,708 of 383,136
- Works
- 63
- Citations
- 2.4k
- Citations per work
- 37.5
What does Yoh Isobe research?
Yoh Isobe's work is mostly in Medicine (66%), Health Professions (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences4570.7%
- Medicine4266.4%
- Health Professions34.3%
- Everything else1829.3%
- 1Surgery32% of their works
- 2Pulmonary and Respiratory Medicine19% of their works
- 3Gastroenterology7% of their works
- 4Oncology6% of their works
- 5General Health Professions4% of their works
- 6Radiology, Nuclear Medicine and Imaging2% of their works
Research topics
- Gastric Cancer Management and Outcomes
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal Tumor Research and Treatment
- Metastasis and carcinoma case studies
- Esophageal Cancer Research and Treatment
- Hernia repair and management
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Appendicitis Diagnosis and Management
Which keywords describe Yoh Isobe's research?
The keywords of their largest research topics: Gastric Cancer, Endoscopic Resection, Chemotherapy, Molecular Characterization, Prognostic Factors, Surgical Management, Helicobacter pylori and Inflammation.
- Diagnosis
- Cholangiocarcinoma
- Mesh Techniques
- Preoperative Chemoradiotherapy
- Metastatic Carcinomas
- Complications
- Imatinib Mesylate
- Meta-Analysis
- Inflammation
- Surgical Management
- Molecular Characterization
- Endoscopic Resection
- Gastric Cancer
- Chemotherapy
- Prognostic Factors
- Helicobacter pylori
- Epidemiology
- Surgery
- Sunitinib
- Lung Tumors
- Esophageal Carcinoma
- Hernia Repair
- Biliary Tract Cancer
- Appendicitis
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 24 words, with their numbers
- Gastric Cancer302 topics
- Endoscopic Resection252 topics
- Chemotherapy181 topic
- Molecular Characterization181 topic
- Prognostic Factors132 topics
- Surgical Management132 topics
- Helicobacter pylori121 topic
- Inflammation121 topic
- Epidemiology112 topics
- Meta-Analysis102 topics
- Surgery102 topics
- Imatinib Mesylate91 topic
- Sunitinib91 topic
- Complications82 topics
- Lung Tumors81 topic
- Metastatic Carcinomas81 topic
- Esophageal Carcinoma71 topic
- Preoperative Chemoradiotherapy71 topic
- Hernia Repair51 topic
- Mesh Techniques51 topic
- Biliary Tract Cancer41 topic
- Cholangiocarcinoma41 topic
- Appendicitis31 topic
- Diagnosis31 topic
Where does Yoh Isobe work?
Yoh Isobe's main affiliation in the publication record is Tokyo Medical Center, Japan.
How many publications and citations does Yoh Isobe have?
OpenAlex counts 63 works and 2,364 citations for Yoh Isobe, an h-index of 18, ranking #1,743,824 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Yoh Isobe. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.